Avadel Pharmaceuticals PLC
F:AWK1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Avadel Pharmaceuticals PLC
F:AWK1
|
IE |
|
Elia Group SA
XBRU:ELI
|
BE |
|
H
|
Hongli Group Inc
NASDAQ:HLP
|
CN |
|
M
|
Mercuries Life Insurance Co Ltd
TWSE:2867
|
TW |
|
World Am Inc
OTC:WOAM
|
US |
|
Voleo Trading Systems Inc
XTSX:TRAD
|
CA |
|
L
|
Linhai Co Ltd
SSE:600099
|
CN |
|
IP Group PLC
LSE:IPO
|
UK |
|
Honghua Group Ltd
HKEX:196
|
CN |
|
C
|
China Sandi Holdings Ltd
HKEX:910
|
HK |
|
North Pacific Bank Ltd
TSE:8524
|
JP |
|
R
|
Rupert's Crossing
XTSX:RUCC.P
|
CA |
|
Ener-Core Inc
OTC:ENCR
|
US |
|
F
|
FNB Corp
F:FN2
|
US |
|
C
|
CHAR Technologies Ltd
OTC:CTRNF
|
CA |
|
Adm Energy PLC
F:P4JC
|
UK |
|
L
|
Li-Metal Corp
OTC:LIMFF
|
CA |
|
N
|
Norvista Capital Corp
XTSX:OC
|
CA |
|
P
|
PT Era Digital Media Tbk
IDX:AWAN
|
ID |
|
L
|
L is B Corp
TSE:145A
|
JP |
|
Enea SA
OTC:ENEAY
|
PL |
|
Blue Foundry Bancorp
F:5P8
|
US |
|
JR Holding Alternatywna Spolka Inwestycyjna SA
F:8JA
|
PL |
|
H
|
Haatz Inc
KOSDAQ:066130
|
KR |
Avadel Pharmaceuticals PLC
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. The company is headquartered in Dublin, Dublin and currently employs 66 full-time employees. The Company’s lead product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness (EDS), and cataplexy in narcolepsy patients. Its Micropump allows for the development of modified and/or controlled release solid, oral dosage formulations of drugs. Its LiquiTime technology allows for development of modified/controlled release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its Medusa technology allows for the development of extended-/modified-release injectable dosage formulations of drugs.
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. The company is headquartered in Dublin, Dublin and currently employs 66 full-time employees. The Company’s lead product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness (EDS), and cataplexy in narcolepsy patients. Its Micropump allows for the development of modified and/or controlled release solid, oral dosage formulations of drugs. Its LiquiTime technology allows for development of modified/controlled release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its Medusa technology allows for the development of extended-/modified-release injectable dosage formulations of drugs.
Revenue Growth: LUMRYZ net revenue hit $68.1 million in Q2, up 64% year-over-year and 30% sequentially.
Profitability: Avadel reported its first-ever net income since the LUMRYZ launch, at $9.7 million or $0.10 per diluted share.
Patient Demand: Active LUMRYZ patients grew to approximately 3,100, a 63% increase from last year, with persistency and reimbursement rates improving.
Raised Guidance: Full-year 2025 revenue guidance was raised to $265–275 million from $255–265 million, reflecting confidence in continued commercial execution.
Clinical Expansion: LUMRYZ received orphan drug designation for idiopathic hypersomnia (IH), with Phase III enrollment underway and potential supplemental NDA filing targeted for the second half of 2026.
Ongoing Investments: Avadel is increasing investments in sales, marketing, and new product development, including a low/no sodium extended-release oxybate.
Legal Clarity: A favorable court ruling affirmed FDA approval of LUMRYZ, and Avadel is pursuing additional legal actions with a major antitrust trial scheduled for November.
